[HTML][HTML] Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma
Z Wang, X Ji, Y Zhang, F Yang, H Su… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Background The incidence of papillary thyroid cancer (PTC) continues to rise all over the
world, 10–15% of the patients have a poor prognosis. Although immunotherapy has been …
world, 10–15% of the patients have a poor prognosis. Although immunotherapy has been …
Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma.
Z Wang, X Ji, Y Zhang, F Yang, H Su… - … for Immunotherapy of …, 2024 - europepmc.org
Background The incidence of papillary thyroid cancer (PTC) continues to rise all over the
world, 10-15% of the patients have a poor prognosis. Although immunotherapy has been …
world, 10-15% of the patients have a poor prognosis. Although immunotherapy has been …
Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma
Z Wang, X Ji, Y Zhang, F Yang, H Su… - Journal for …, 2024 - pubmed.ncbi.nlm.nih.gov
Background The incidence of papillary thyroid cancer (PTC) continues to rise all over the
world, 10-15% of the patients have a poor prognosis. Although immunotherapy has been …
world, 10-15% of the patients have a poor prognosis. Although immunotherapy has been …
[HTML][HTML] Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma
Z Wang, X Ji, Y Zhang, F Yang, H Su, H Zhang… - … for ImmunoTherapy of …, 2024 - jitc.bmj.com
Background The incidence of papillary thyroid cancer (PTC) continues to rise all over the
world, 10–15% of the patients have a poor prognosis. Although immunotherapy has been …
world, 10–15% of the patients have a poor prognosis. Although immunotherapy has been …